Skip to main content

Table 2 Clinical studies of NK cell based immunotherapy in the HCC patients

From: Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review

Interventions Design Strategy (brief summary) Recruitment status Clinicaltrials.gov identifier
“Safety and effectiveness study of autologous natural killer and natural killer t cells on cancer” including HCC Phase I NK cell and NKT cell-based autologous adoptive immunotherapy Suspended NCT00909558
“Evaluate the efficacy and safety of MG4101 (ex vivo expanded allogeneic NK cell)” Phase 2 NK cell transfer after curative liver resection on the patient with advanced HCC Completed NCT02008929
By using adoptive transfer of autologous NK cells to prevent recurrence of hepatocellular carcinoma after curative therapy Phase 2 Adjuvant adoptive immune therapy using NK cell in patient undergone curative resection (RFA or operation) Not yet recruiting NCT02725996
Safety study of NK cells from sibship to treat the recurrence of HCC after liver transplantation Phase 1 Conventional treatment and NK cell transfer Recruiting NCT02399735
A study of MG4101 (allogeneic natural killer cell) for intermediate-stage of hepatocellular carcinoma Phase 2 Allogeneic natural killer cell transfer after transarterial chemoembolization Recruiting NCT02854839
Safety study of liver natural killer cell therapy for hepatoma liver transplantation (MIAMINK) Phase 1 Liver transplantation and liver NK cell inoculation Completed NCT01147380
Recombinant vesicular stomatitis virus expressing IFN-β and probable exertion of anti-tumor activity of NK cells against adult HCC Phase I Cytokine therapy Recruiting NCT01628640